🇺🇸 FDA
Company

RHYTHM

RHYTHM PHARMACEUTICALS, INC.

RYTM pharma USA

Quick answer

RHYTHM is a pharma company (RYTM) headquartered in BOSTON, MA, USA with 24 tracked pipeline programs.

Pipeline (24)

project

CRT with triple site ventricular stimulation

Heart Failure

Phase 3 · other · completed

1 trials project

Class I or III Antiarrhythmic Medications

Atrial Fibrillation

Phase 3 · small_molecule · completed

1 trials project

Coronary artery bypass grafting

Ischemic Heart Failure

Phase 3 · other · completed

1 trials project

Flecainide or Sotalol or Propafenone

Paroxysmal Atrial Fibrillation

Phase 3 · small_molecule · completed

1 trials project

Medtronic Talent Stent-Graft-System

Aortic Diseases

Phase 3 · other · completed

1 trials project

Setmelanotide

Obesity

Phase 3 · small_molecule · active

1 trials project

Setmelanotide

Bardet-Biedl Syndrome

Phase 3 · small_molecule · completed

1 trials project

Setmelanotide

Obesity Associated With Defects in Leptin-melanocortin Pathway

Phase 3 · small_molecule · active

2 trials project

Setmelanotide

Bardet Biedl Syndrome (BBS)

Phase 3 · small_molecule · completed

1 trials project

Setmelanotide

Hypothalamic Obesity

Phase 3 · small_molecule · active

3 trials project

Setmelanotide

Pro-opiomelanocortin (POMC) Deficiency Obesity

Phase 3 · small_molecule · completed

1 trials project

Setmelanotide

Leptin Receptor Deficiency Obesity

Phase 3 · small_molecule · completed

1 trials project

Setmelanotide 2 mg

Bardet-Biedl Syndrome

Phase 3 · small_molecule · completed

1 trials project

Ventricular Assist Device System

Heart Failure

Phase 3 · other · completed

1 trials project

Bivamelagon

Hypothalamic Obesity

Phase 2 · small_molecule · active

1 trials project

Diuretics

Heart Failure

Phase 2 · small_molecule · completed

1 trials project

LB54640

Hypothalamic Obesity

Phase 2 · small_molecule · completed

1 trials project

Medtronic PrimeADVANCED Neurostimulator

Heart Failure

Phase 2 · other · completed

1 trials project

PCI

Myocardial Infarction

Phase 2 · other · completed

1 trials project

Part A: RM-718 or placebo (matched to specific RM-718 dose cohort)

Hypothalamic Obesity

Phase 2 · small_molecule · active

1 trials project

Setmelanotide

Genetic Obesity

Phase 2 · small_molecule · completed

2 trials project

Setmelanotide

Overweight and Obesity

Phase 2 · small_molecule · completed

1 trials project

Setmelanotide

Hypertriglyceridemia

Phase 2 · small_molecule · completed

1 trials project

Setmelanotide

Overweight

Phase 2 · small_molecule · completed

1 trials

Drugs (1)

drug

setmelanotide acetate

IMCIVREE

Patents (8)

patent

US 12285460

Pharmaceutical compositions

Expires Mon Apr 24 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12263202

Method of treating melanocortin-4 receptor pathway-associated disorders

Expires Mon Mar 27 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12077612

Peptide compositions

Expires Mon Aug 29 2044 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11702448

Method of treating melanocortin-4 receptor-associated disorders in heterozygous

Expires Mon Jul 13 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11129869

Pharmaceutical compositions

Expires Mon Sep 23 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10960046

Method of treating melanocortin-4 receptor pathway-associated disorders

Expires Mon Mar 25 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10954268

Method of treating melanocortin-4 receptor-associated disorders in heterozygous

Expires Mon Mar 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10858399

Peptide compositions

Expires Mon Dec 03 2040 00:00:00 GMT+0000 (Coordinated Universal Time)